3M Drug Delivery Systems Collaborates with Avant Immunotherapeutics on Vaccine Adjuvants

ST. PAUL, Minn.--(BUSINESS WIRE)--3M Drug Delivery Systems announces the signing of a non-exclusive license agreement with Celldex Therapeutics, Inc. (a wholly-owned subsidiary of AVANT Immunotherapeutics). Under the agreement, 3M will provide its patented toll-like receptor (TLR) agonist compounds to Celldex for an undisclosed licensing fee, milestones and royalties.

Back to news